Hong Kong stocks surged | Hutchison Pharma (01276.HK) rose by nearly 3% as Fumarsu Tege Dilin Injection clinical trial approved.

According to the Securities Times app, Hutchison Medicine (01276.HK) rose nearly 3%, as of the publication, rose 1.76%, reported 72.35 Hong Kong dollars, with a turnover of 37.5886 million Hong Kong dollars.